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Heavy menstrual bleeding, or men-orrhagia,­is­a­common­problem­that­can­have­a­significant­effect­on­women’s­lives­
and­ can­ burden­ both­ patients­ and­ health­ care­
systems.1,2­Menorrhagia­ accounts­ for­ 18.5%­ of­
gynecologist­ office­ visits­ in­ the­United­ States3­
and­for­20%­in­the­United­Kingdom4;­more­than­
5%­of­women­who­are­30­to­49­years­of­age­con­







jective­ measures­ of­ menstrual­blood­ loss­ and­
women’s­ perception­ of­ the­ amount­ of­ bleed­
ing.8,9­Only­about­half­the­women­with­menor­
rhagia­who­present­to­health­care­providers­have­


















HealthCare)­ has­ been­ available­ to­ treat­ this­
problem.­Although­developed­as­a­contraceptive,­
the­ le­vo­nor­ges­trel­IUS­ also­ reduces­ menstrual­
blood­ loss.13­ In­ 2007,­ U.K.­ guidelines10­ intro­





pared­ with­ nonhormonal­ and­ hormonal­ treat­
ments,­ showed­ that­ the­ le­vo­nor­ges­trel­IUS­ re­
sulted­in­a­greater­reduction­in­menstrual­blood­
loss­ at­3­ to­12­months­of­ follow­up.13,14­How­
ever,­ it­ is­ not­ clear­ whether­ these­ short­term­





The­ Effectiveness­ and­ Cost­Effectiveness­ of­
Le­vo­nor­ges­trel­Containing­ Intrauterine­ System­
in­Primary­Care­against­Standard­Treatment­for­
Menorrhagia­ (ECLIPSE)­ trial­ was­ a­ pragmatic,­
multicenter,­randomized­trial­that­compared­the­






sented­ to­ their­ primary­ care­ physicians­ with­
menorrhagia­involving­at­least­three­consecutive­












of­ endometrial­biopsy­were­ reported­ to­be­nor­
mal;­no­further­investigations­were­mandated­by­




phone­ or­ a­ Web­based­ central­ randomization­
service­at­the­University­of­Birmingham­Clinical­
Trials­Unit.­A­computerized,­minimized­random­
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treatment­ options­ included­ mefenamic­ acid,­
tranexamic­acid,­norethindrone,­a­combined­es­


















Outcome Measures and Follow-Up
The­ primary­ outcome­ measure­ was­ the­ condi­
tion­specific­ Menorrhagia­ Multi­Attribute­ Scale­
(MMAS),17,18­which­ is­designed­ to­measure­ the­
effect­of­menorrhagia­on­six­domains­of­daily­life­
(practical­ difficulties,­ social­ life,­ psychological­
health,­physical­health,­work­and­daily­routine,­











Health­ Survey­ (SF­36),­ version­ 2­ (with­ scores­
ranging­ from­ 0­ [severely­ affected]­ to­ 100­ [not­
affected]);­the­EuroQol­Group­5­Dimension­Self­
Report­Questionnaire­(EQ­5D)­descriptive­system­









(assessed­ relative­ to­ perceived­usual­ activity­ as­
an­ ordinal­ response).23­ Scores­ were­ obtained­
before­randomization­and­by­mail­at­6­months,­
1­ year,­ and­ 2­ years­ after­ randomization.­ Data­
were­collected­ from­participating­clinicians­ re­
garding­ all­ serious­ adverse­ events,­ defined­ as­
adverse­events­that­resulted­in­death,­disability,­
or­ hospitalization.­ Patients­ were­ also­ asked­ to­













mittee,­ and­ clinical­ trial­ authorization­ was­





see­ the­ Supplementary­ Appendix,­ available­ at­
NEJM.org.)­ All­ medications­ and­ devices­ were­
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differences­ in­efficacy­within­prespecified­sub­
groups.­ Changes­ from­ baseline­ scores­ within­
treatment­groups­were­compared­with­the­use­of­
paired­ t­tests.­ Several­ sensitivity­ analyses­ were­
also­performed­on­the­primary­outcome­measure­
to­ test­ the­ robustness­of­ the­ results.­These­ in­













SAS­ software,­ version­ 9.2­ (SAS­ Institute),­ was­















tary­Appendix);­55­ (19%)­of­ the­women­ in­ the­
usual­treatment­ group­ required­ contraception.­










no­ treatment,­ and­ 8­ underwent­ unsuccessful­
insertion­ of­ the­ system­ and­were­ subsequently­
given­usual­medical­ treatment­(Fig.­1).­Women­
in­ the­ le­vo­nor­ges­trel­IUS­ group­ were­ almost­
twice­ as­ likely­ as­ those­ in­ the­ usual­treatment­





















No. of patients 286 285
Age
≥35 yr — no. of patients (%)† 255 (89) 257 (90)
Mean — yr 41.8±5.5 42.1±5.0
Body-mass index‡
>25 — no. of patients (%)† 200 (70) 200 (70)
Mean 29.3±6.7 29.1±6.1
Race — no. of patients (%)§
White 246 (86) 225 (79)
Asian 23 (8) 28 (10)
Black 12 (4) 18 (6)
Mixed 4 (1) 9 (3)
Other 1 (<1) 4 (1)
Duration of menorrhagia ≥1 yr —  
no. of patients (%)†
229 (80) 231 (81)
Menstrual pain — no. of patients (%)† 211 (74) 213 (75)
Contraceptive requirement — no. of  
patients (%)†
55 (19) 55 (19)
Copper or nonhormonal coil in place — 
no. of patients (%)
10 (3) 9 (3)
* Plus–minus values are means ±SD. There were no significant differences  
between groups for any of the characteristics. Levonorgestrel-IUS denotes  
levonorgestrel-releasing intrauterine system.
† This characteristic was a stratification variable and was assessed in predefined 
subgroup analyses.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
§ Race was self-reported, with one response not given in the levonorgestrel-IUS 
group.
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571 Underwent randomization
1132 Were approached for consent after
meeting eligibility criteria
561 Were excluded
190 Had preference for usual medical treatment
130 Had preference for levonorgestrel-IUS
86 Declined to participate
25 Wanted referral to secondary care
3 Did not want any treatment
3 Intended to become pregnant
124 Did not give reason
286 Were assigned to receive usual
medical treatment
6 Did not take treatment
5 Decided to take no treatment
1 Underwent levonorgestrel-IUS insertion
285 Were assigned to receive levonorgestrel-IUS
24 Did not undergo insertion
10 Decided to have usual medical
treatment
8 Underwent unsuccessful insertion and
were given usual medical treatment
6 Decided to take no treatment
33 Exited trial
6 Were lost to follow-up
27 Were contacted and 
did not wish to complete
any more questionnaires
22 Exited trial
6 Were lost to follow-up
16 Were contacted and 
did not wish to complete
any more questionnaires
209 Returned questionnaire booklet at 6 mo
57 Discontinued treatment
35 Underwent levonorgestrel-IUS insertion
22 Decided to take no treatment
218 Returned questionnaire booklet at 6 mo
26 Discontinued treatment
12 Changed to usual medical treatment 
14 Decided to take no treatment
8 Exited trial
2 Were lost to follow-up
6 Were contacted and 
did not wish to complete
any more questionnaires
8 Exited trial
3 Were lost to follow-up
5 Were contacted and 
did not wish to complete
any more questionnaires
220 Returned questionnaire booklet at 1 yr
42 Discontinued treatment
21 Underwent levonorgestrel-IUS insertion
21 Decided to take no treatment
219 Returned questionnaire booklet at 1 yr
21 Discontinued treatment
9 Changed to usual medical treatment
12 Decided to take no treatment
14 Exited trial
8 Were lost to follow-up
6 Were contacted and 




4 Were lost to follow-up
3 Were contacted and 
did not wish to complete
any more questionnaires
231 Returned questionnaire booklet at 2 yr
64 Discontinued treatment
24 Underwent levonorgestrel-IUS insertion
40 Decided to take no treatment
247 Returned questionnaire booklet at 2 yr
32 Discontinued treatment
8 Changed to usual medical treatment
24 Decided to take no treatment
Figure 1. Enrollment, Randomization, and Follow-up of the Study Patients.
Reasons for discontinuation of treatment can be found in Tables S3a and S3b in the Supplementary Appendix. Le vo nor-
ges trel-IUS denotes le vo nor ges trel-releasing intrauterine system.
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ent­ from­ the­ results­ of­ the­ primary­ analysis­





in­ women­ with­ a­ BMI­ above­ 25­ (16.7­ MMAS­































































Figure 2. Time to First Treatment Change during the 2-Year Study Period.
Data are for women who crossed over from the assigned study treatment 





































0 6 12 24
Figure 3. Primary Outcome in the Two Treatment Groups.
The primary outcome was the score on the Menorrhagia Multi-Attribute 
Scale (MMAS) (scores range from 0 to 100, with lower scores indicating 
greater severity). Mean MMAS scores are shown for the two groups at  
6, 12, and 24 months. I bars indicate 95% confidence intervals. Overall, the 
average difference in scores between the women treated with the le vo nor ges-
trel-IUS and those treated with the usual medical therapy was 13.4 points 
(95% confidence interval, 9.9 to 16.9; P<0.001).
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(Table­2);­mental­health­was­the­only­domain­for­
which­there­were­no­significant­between­group­
differences.­ The­ improvements­ appeared­ to­ be­






but­not­at­earlier­assessments­ (Table­S8­ in­ the­
Supplementary­ Appendix).­ Nor­ did­ the­ treat­
















for­menorrhagia,­ leads­ to­greater­ improvement­
Table 2. Scores on the Quality-of-Life and Sexual-Activity Questionnaires at Baseline, and Mean Between-Group 
Difference over 2 Years.*
Questionnaire Score at Baseline
Between-Group  
Difference in Score  






Physical functioning 77.8±24.7 80.0±20.4 2.7 (0.0 to 5.4) 0.05
Physical role 68.9±26.2 72.1±24.7 5.9 (2.6 to 9.1) <0.001
Emotional role 69.8±26.8 71.9±25.1 4.6 (1.3 to 8.0) 0.007
Social functioning 62.4±25.9 64.3±24.5 5.1 (2.0 to 8.1) 0.001
Mental health 59.0±19.8 60.3±19.3 1.5 (−1.0 to 3.9) 0.23
Energy and vitality 40.8±21.7 40.7±20.9 5.3 (2.5 to 8.2) <0.001
Pain 49.5±24.9 54.2±24.9 7.8 (4.5 to 11.0)§ <0.001
Perception of general health 60.3±21.9 61.8±21.4 2.9 (−0.3 to 5.4) 0.03
EQ-5D descriptive system¶ 0.714±0.276 0.756±0.243 0.013 (−0.016 to 0.042) 0.38
EQ-5D visual-analogue scale‖ 69.7±19.8 70.3±19.1 2.0 (−0.5 to 4.6)§ 0.12
Sexual Activity Questionnaire**
Pleasure 10.9±4.9 10.8±4.9 0.4 (−0.3 to 1.1) 0.26
Discomfort 4.62±1.69 4.65±1.48 −0.07 (−0.30 to 0.16) 0.55
* Plus–minus values are means ±SD.
† Estimated values greater than zero favor the levonorgestrel-IUS. These are summary results only; see the 
Supplementary Appendix for the complete results and for details of the repeated-measures model used to calculate 
these values.
‡ The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is a general health-related quality-of-life 
questionnaire. Scores in each of the eight domains range from 0 (severely affected) to 100 (not affected).
§ There is some evidence of a time-by-treatment effect (P≤0.05); see the Supplementary Appendix for full details of the 
estimates at each time point.
¶ The EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D) descriptive system is a general health-related 
quality-of-life questionnaire. Scores range from −0.59 (state of health worse than death) to 1.00 (perfect state of 
health).
‖ Scores on the EQ-5D visual-analogue scale range from 0 (worst health state imaginable) to 100 (most perfect health 
state imaginable).
** The Sexual Activity Questionnaire is designed to assess the possible effect of treatment on sexual functioning. Scores 
for pleasure range from 0 (lowest level) to 18 (highest level), and scores for discomfort range from 0 (greatest) to 6 (none).
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in­women’s­ assessments­of­ the­ effect­ of­heavy­












ges­trel­IUS­ than­ with­ usual­ medical­ treatment.­
The­ average­ between­group­ difference­ in­ the­
overall­MMAS­score­over­2­years­of­follow­up­was­
13.4­points,­with­greater­improvement­in­the­le­







life­ measures.29­ A­ 13.4­point­ difference­ repre­
sents­a­change­in­two­or­three­MMAS­domains:­
from­being­substantially­ to­minimally­ affected­
by­ menorrhagia­ (e.g.,­ from­ frequent­ to­ occa­
sional­disruptions­of­work­and­daily­routine)­or­
from­ being­ minimally­ affected­ to­ being­ unaf­
fected­ (e.g.,­ from­ experiencing­ some­ strain­ in­
family­ life­ to­ experiencing­ no­ strain­ in­ family­
life).­ The­ between­group­ difference­ reported­








sentative­ of­ the­ U.K.­ population,­ the­ relatively­
























with­perfect­ compliance.­A­ range­of­ sensitivity­
analyses­did­not­change­the­conclusions.­Although­




tings,­ and­ in­ some­ circumstances,­ it­ requires­
consultation­with­a­gynecologist.
The­21.4­point­improvement­from­baseline­in­
the­ average­ MMAS­ score­ at­ 6­ months­ in­ the­
usual­treatment­ group,­ which­ was­ sustained­
throughout­ the­ 2­ years­ of­ follow­up,­ was­ not­
explained­by­a­switch­in­treatment,­since­similar­
improvements­ were­ noted­ when­ crossovers­ to­
the­ le­vo­nor­ges­trel­IUS­ were­ excluded­ from­ the­
analyses.­The­higher­rate­of­discontinuation­ in­





Nonetheless,­ at­ 2­ years,­ 36%­of­women­ in­ the­
le­vo­nor­ges­trel­IUS­ group­ had­ had­ the­ system­
removed,­generally­owing­to­lack­of­effectiveness­
or­to­irregular­or­prolonged­bleeding,­which­are­
well­recognized­ reasons­ for­ discontinuing­ the­
le­vo­nor­ges­trel­IUS.31,32­This­proportion­is­consis­
tent­with­the­proportions­of­women­who­discon­
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sis­ was­ one­ of­ several­ subgroup­ analyses­ and­
should­ be­ interpreted­ with­ caution,­ since­ the­
findings­ may­ be­ explained­ by­ chance­ and­ re­
quire­confirmation.
We­ expected­ fewer­ surgical­ interventions­ in­
the­ le­vo­nor­ges­trel­IUS­ group,­ but­ rates­ were­
similarly­ low­ in­ the­ two­ groups.­ This­ finding­
may­ reflect­ the­ eligibility­ criteria­ for­ the­ trial,­
since­women­who­had­ fibroids­or­ other­ disor­
ders­were­excluded.
Finally,­given­the­long­natural­history­of­men­






reduced­ the­ adverse­ effect­ of­ menorrhagia­ on­
women’s­lives­over­the­course­of­2­years,­but­the­
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